Recently, CDP, an international authoritative environmental non-profit organization, announced the climate change rating results for disclosing companies in 2023. Sino Biopharm's rating was upgraded by two levels to "B" for its outstanding performance in climate change management and disclosure, reaching a leading level in the domestic industry.

In recent years, Sino Biopharm has actively undertaken various initiatives to address the challenges of climate change and promote a green, low-carbon transformation of the enterprise. In 2022, the Group established greenhouse gas emission reduction targets and advanced decarbonization efforts through multiple dimensions, including the application of clean energy and energy-saving measures, achieving significant results. In 2023, the Group launched the "Carbon Neutrality Pathway Planning Project", aiming to formulate carbon neutrality goals and pathways that align with the corporate development strategy. It is effectively reducing greenhouse gas emissions by systematically promoting measures such as process optimization, upgrading of high-energy-consumption equipment, application of renewable energy, and construction of a green industrial chain.

This rating upgrade highlights the recognition of Sino Biopharm's climate change management and information disclosure by international professional institutions. In the future, the Group will further enhance its climate risk management capabilities, carry out high-quality greenhouse gas emission reduction work, and drive synergistic efforts across the industrial chain, contributing to the promotion of green and sustainable global economic development.